Scientists have identified a small protein that boosts signals from cell receptors targeted by many medicines. The protein is called p11. The discovery was published in Science Advances.

The team systematically tested p11 across the GPCR family of receptors. GPCRs are involved in many common diseases. They are also frequent targets of drugs. Experiments showed that p11 enhanced PAR2 signalling and strengthened cellular responses.

To check real-world relevance, researchers studied mice lacking p11. When PAR2 signalling was activated, these mice showed a weaker inflammatory response than normal mice. This showed that p11 amplifies inflammatory signalling pathways in living organisms.

The findings point to new directions for drug development. Therapies that influence how p11 interacts with specific receptors could fine-tune signalling in chronic pain and inflammatory disorders. The study gives fresh insight into how cells communicate. It may lead to more precise treatments in the future. GPCRs sit on cell surfaces and pass signals inward. About a third of all prescription drugs act on them. Understanding how proteins like p11 tune their activity is valuable basic science. The next step is testing whether the effect holds across more receptors. Drug designers may one day adjust p11 interactions to reduce side effects.